New encapsulated cancer drug enters human testing
NCT ID NCT03207672
Summary
This is an early-stage (Phase 1) study to find a safe dose and check the side effects of a new, encapsulated form of a cancer drug called E7389. It is being tested in adults with advanced solid tumors that have not responded to standard treatments. The study will also look at how the drug moves through the body and if it shows any signs of helping to shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai Trial Site 1
Chuo-ku, Tokyo, Japan
-
Eisai Trial Site 10
Hidaka, Saitama, Japan
-
Eisai Trial Site 11
Kyoto, Japan
-
Eisai Trial Site 12
Fukuoka, Japan
-
Eisai Trial Site 2
Osaka, Japan
-
Eisai Trial Site 3
Kashiwa, Chiba, Japan
-
Eisai Trial Site 4
Koto-ku, Tokyo, Japan
-
Eisai Trial Site 5
Sapporo, Hokkaido, Japan
-
Eisai Trial Site 6
Yokohama, Kanagawa, Japan
-
Eisai Trial Site 7
Shinjuku-ku, Tokyo, Japan
-
Eisai Trial Site 8
Nishinomiya, Hyōgo, Japan
-
Eisai Trial Site 9
Bunkyo-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.